期刊文献+

探讨聚乙二醇化干扰素α-2a对慢性乙型肝炎的疗效

原文传递
导出
摘要 目的:探讨聚乙二醇化干扰素α-2a对慢性乙型肝炎的临床疗效。方法:回顾性分析接受聚乙二醇化干扰素α-2a治疗的38例慢性乙型肝炎患者的临床资料。结果:给予聚乙二醇化干扰素α-2a治疗8周的慢性乙型肝炎患者即可取得血清学及病毒学方面的应答,疗程满48周时ALT复常27例(ALT复常率为71.1%)、HBV DNA阴转33例(阴转率86.8%)、HBeAg阴转33例(阴转率24.2%)、HBeAg血清转换15例(阴转率45.4%)。结论:聚乙二醇化干扰素α-2a对慢性乙型肝炎患者具有明显的疗效。
作者 张广林
出处 《亚太传统医药》 2012年第8期115-116,共2页 Asia-Pacific Traditional Medicine
  • 相关文献

参考文献3

二级参考文献26

  • 1张定凤.乙型肝炎的治疗面临新的挑战[J].中华肝脏病杂志,2005,13(7):481-483. 被引量:9
  • 2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 3[1]Xu ZX, Hoffman J, Patel I, et al. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon ( PEG-IFN ) and interferon α-2a(IFNα-2a)to healthy subjects[J]. Hepatology, 1998,28(4 pt 2):702A.
  • 4[2]Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG)and moiety optimizes the pharmacokinetics(PK) of pegIFNα-2a( PEG-IFN)and may explain its enhanced efficacy in chronic hepatitis C (CHC) [ J ]. Hepatology,1999,30(4 pt 2): 190A.
  • 5[3]Modi MW, Fried M, Reindollar RW, et al. The pharmacokinetic behavior of pegylated (40kDa) interferon alfa-2a ( PEGASYS TM)in chronic hepatitis C patients after multiple dosing[J]. Hepatology,2000,32 (4 pt 2) :394A.
  • 6[4]Perry CM, Jarvis B. Peginterferon α-2a (40kD):a review of its use in the management of chronic hepatitis C[ J ]. Drugs, 2001,61:2263 - 2288.
  • 7[5]Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a [ J ]. Ann Pharmacother, 2002,36: 933 - 935.
  • 8[6]Modi MW, Fulton JS, Buckmann DK, et al. Clearance of pegylated (40kDa) interferon alfa-2a ( PEGASYSTM ) is primarily hepatic[J]. Hepatology ,2000,32(4 pt 2) :371A.
  • 9[7]Sy S,Algranti NE,Patel IH,et al. Cytochrome P450(CYP)-mediated drug interactions are unlikely with peginterferon α-2a(PEG-IFN)except for CYP1A2[J]. Hepatology, 1999,30:193A.
  • 10[8]Zeuzem S, Feinman SV, Rasenack J, et al, Peginterferon alfa-2a in patients with chronic hepatitis C[J]. New Engl J Med ,2000,343:1666 - 1672.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部